Drug Type T-lymphocyte cell therapy |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Leukemia | Preclinical | United States | 29 Mar 2024 | |
Lymphoma | Preclinical | United States | 29 Mar 2024 |